Our research group identified abnormal MAP2K7 activation in pediatric T-ALL and conducted proof-of-concept evaluations of 5Z-7Oxozeaenol and OTSSP167 compounds. Here, MAP2K7 is linked to acute lymphoblastic leukemia.